The invention provides compositions comprising cyclodextrins encapsulating a selective ATP inhibitor, as well as uses thereof.

The invention provides compositions comprising cyclodextrins encapsulating a selective ATP inhibitor, as well as uses thereof.

The invention provides compositions comprising cyclodextrins encapsulating a selective ATP inhibitor, as well as uses thereof.

A gas mixing system for providing mixed gas for intraocular injection. In some embodiments, a first fixed-volume chamber is automatically purged and filled with gas from a first gas supply input, to a first predetermined pressure. A second fixed-volume chamber is purged and filled with gas from a second gas supply input, to a second predetermined pressure. The first and second predetermined pressures are determined based on a desired concentration of gases in the final mix, and the respective volumes of the first and second fixed-volume chambers and of a third fixed-volume chamber. Gas from the first fixed-volume chamber is then allowed to mix with gas in the third fixed-volume chamber, which was previously purged. Next, gas from the second fixed-volume chamber is allowed to mix with gas in the third fixed-volume chamber. Finally, the mixture of gases in the third fixed-volume chamber is expressed into an intraocular syringe.

A gas mixing system for providing mixed gas for intraocular injection. In some embodiments, a first fixed-volume chamber is automatically purged and filled with gas from a first gas supply input, to a first predetermined pressure. A second fixed-volume chamber is purged and filled with gas from a second gas supply input, to a second predetermined pressure. The first and second predetermined pressures are determined based on a desired concentration of gases in the final mix, and the respective volumes of the first and second fixed-volume chambers and of a third fixed-volume chamber. Gas from the first fixed-volume chamber is then allowed to mix with gas in the third fixed-volume chamber, which was previously purged. Next, gas from the second fixed-volume chamber is allowed to mix with gas in the third fixed-volume chamber. Finally, the mixture of gases in the third fixed-volume chamber is expressed into an intraocular syringe.

The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.

The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.

The present disclosure is directed to a method of treating a neuropsychiatric disorder. This method involves selecting a subject having the neuropsychiatric disorder and administering to the selected subject a preparation of glial progenitor cells at a dosage effective to treat the neuropsychiatric disorder in the subject. Another aspect of the disclosure is directed to a method of treating a neuropsychiatric disorder that includes selecting a subject having the neuropsychiatric disorder and administering, to the selected subject, a potassium (K.sup.+) channel activator at a dosage effective to restore normal brain interstitial glial K.sup.+ levels in the selected subject and treat the neuropsychiatric disorder is also disclosed.

A fluorocarbon emulsion in water for use in fractionated radiotherapy and chemotherapy, wherein said fluorocarbon comprises between 4 and 8 carbon atoms.

A fluorocarbon emulsion in water for use in fractionated radiotherapy and chemotherapy, wherein said fluorocarbon comprises between 4 and 8 carbon atoms.